<p>Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer</p>-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer

Published:2020-05 Issue: Volume:Volume 13 Page:4113-4122
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Zhu Zhen,Ling Lanlan,Qi Lezhong,Chong Yue,Xue Li

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference31 articles.

1. Epidemiology. Epidemic rates of cancer incidence in Latin America. Nat Rev Clin Oncol. 2013;10(6):304. doi:10.1038/nrclinonc.2013.77

2. Cancer Statistics, 2008

3. China. Chinese guidelines for diagnosis and treatment of prostate cancer 2018 (English version). Chin J Cancer Res. 2019;31(1):67–83. doi:10.21147/j.issn.1000-9604.2019.01.04

4. A novel isoform of the B cell tyrosine kinase BTK protects breast cancer cells from apoptosis

5. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib Modulates Proliferation, Migration, Mitochondrial Homeostasis, and Apoptosis in Melanoma Cells;Biomedicines;2024-05-04

2. Ibrutinib topical delivery for melanoma treatment: The effect of nanostructured lipid carriers’ composition on the controlled drug skin deposition;Colloids and Surfaces B: Biointerfaces;2024-05

3. Quality by design accredited self-nanoemulsifying delivery of ibrutinib for extenuating the fast-fed variability, ameliorating the anticancer activity and oral bioavailability in prostate cancer;Journal of Drug Delivery Science and Technology;2023-11

4. Prostate cancer immunotherapy: Improving clinical outcomes with a multi-pronged approach;Cell Reports Medicine;2023-10

5. AI & experimental-based discovery and preclinical IND-enabling studies of selective BMX inhibitors for development of cancer therapeutics;International Journal of Pharmaceutics;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3